Totect

Totect is a brand name of dexrazoxane, approved by the FDA in the following formulation(s):

TOTECT (dexrazoxane hydrochloride - injectable; injection)

• 
  Manufacturer: TOPOTARGET
  
  Approval date: September 6, 2007
  
  Strength(s): EQ 500MG BASE/VIAL ^[RLD]

Has a generic version of Totect been approved?

No. There is currently no therapeutically equivalent version of Totect available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Totect. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Treatment of accidental extravasation of anthracyclines
  Patent 6,727,253
  Issued: April 27, 2004
  Inventor(s): Seppo W.; Langer & Peter B.; Jensen & Maxwell; Sehested
  Assignee(s): Antianthra APS
  The present invention relates to a method for pharmacological treatment of accidental extravasation of topoisomerase II poisons, such as anthracyclines. In particular, the invention relates to the use of a topo II catalytic inhibitor, such as the bisdioxopiperazine ICRF-187, for the treatment of an accidental extravasation of a topoisomerase II poison. A method for treatment of such extravasation of a topoisomerase poison such as the anthracyclines, daunorubicin, doxorubicin, epirubicin, or idarubicin is disclosed.
  
  Patent expiration dates:
  
  
  • March 13, 2020
    
    ✓ 
    Patent use: TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 6, 2010 - NEW PRODUCT
  
  
  • September 6, 2014 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Totect Consumer Information (Drugs.com)
• Totect Consumer Information (Cerner Multum)
• Totect Advanced Consumer Information (Micromedex)
• Dexrazoxane Consumer Information (Wolters Kluwer)
• Dexrazoxane Consumer Information (Cerner Multum)
• Dexrazoxane Intravenous Advanced Consumer Information (Micromedex)
• Dexrazoxane Hydrochloride AHFS DI Monographs (ASHP)